EUVIMEDOpdag EUVIMED
Crossref

Immunomodulatory antibodies for therapy of cancer

Ingegerd Hellstrom, Min Dai, Karl Erik Hellstrom

HAMDAN MEDICAL JOURNAL · 2014

DOI: 10.7707/hmj.404 ↗

At a glance

Journal article in HAMDAN MEDICAL JOURNAL, 2014. Written by Ingegerd Hellstrom and 2 co-authors.

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

It has been known for many years that immunological mechanisms play a key role in cancers, including those which are most common in humans. However, for several decades, the benefit of active immunotherapy was modest. This situation is now rapidly changing. In particular, systemic administration of immunomodulatory monoclonal antibodies (mAbs) has demonstrated clinical efficacy, including complete remission in several patients treated at tolerable toxicity for melanoma or other particular types of tumours.6,7 These findings are remarkable but much remains to be learned.

Cite

APA

Hellstrom, I., Dai, M., & Hellstrom, K. E. (2014). Immunomodulatory antibodies for therapy of cancer. HAMDAN MEDICAL JOURNAL. https://doi.org/10.7707/hmj.404

Vancouver

Hellstrom I, Dai M, Hellstrom KE. Immunomodulatory antibodies for therapy of cancer. HAMDAN MEDICAL JOURNAL. 2014. doi:10.7707/hmj.404

BibTeX
@article{Hellstrom2014,
  author = {Hellstrom, Ingegerd and Dai, Min and Hellstrom, Karl Erik},
  title = {Immunomodulatory antibodies for therapy of cancer},
  journal = {HAMDAN MEDICAL JOURNAL},
  year = {2014},
  doi = {10.7707/hmj.404}
}
Start for free →